[Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study].
OBJECTIVE
To investigate the anti-HBV efficacy of bifendate in treatment of chronic hepatitis B.


METHODS
A total of 119 patients with chronic hepatitis B were randomly divided into treatment group (n = 65, aged 24 +/- 12) and control group (n = 54, aged 25 +/- 11). In the treatment group every patient was given higher doses bifendate pills (</= 12 age, 30 approximately 45 mg/d; > 12 age, 45 approximately 67.5 mg/d) for up to 12 months. Hepatic function test was performed and HBeAg, HBeAb and HBV DNA were detected at regular intervals in all patients.


RESULTS
The serum alanine amonotransferase (ALT) decreased to normal only one month later in 70.76% of patients in the treatment group and decreased to normal at least in 2 approximately 3 months in the control group (P < 0.01). The serum conversion rates of HBeAg, HBeAb and HBV DNA in the treatment group were 44.4%, 29.3%, 38.5%, respectively, which were significantly higher than those in the control group (P < 0.01). No noticeable side effect was observed.


CONCLUSIONS
Higher doses of bifendate taken for a long term has remarkable anti-HBV efficacy in treatment of chronic hepatitis B.
Cui
Sunan
S
Jinan Infectious Disease Hospital, Jinan 250021, China.
Wang
Mingming
M
Fan
Guiling
G
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D016896:Treatment Outcome
D000998:Antiviral Agents; D001713:Biphenyl Compounds; C465548:bifendate